Brief: Aligos Therapeutics Presents Clinical Data For Its Nash Program And Nonclinical Data For Its Chronic Hepatitis B Portfolio At AASLD's The Liver Meeting 2022
04/11/2022 12:17
Nov 4 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS PRESENTS CLINICAL DATA FOR ITS NASH
PROGRAM
AND NONCLINICAL DATA FOR ITS CHRONIC HEPATITIS B PORTFOLIO AT
AASLD’S THE LIVER MEETING® 2022
* ALIGOS THERAPEUTICS INC - ALG-055009 DEMONSTRATED
DOSE-DEPENDENT REDUCTIONS IN SEVERAL ATHEROGENIC LIPIDS
* ALIGOS THERAPEUTICS INC - ALG-055009 DEMONSTRATED A
FAVORABLE
PHARMACOKINETIC PROFILE IN SUBJECTS WITH HYPERLIPIDEMIA
Source text for Eikon: ID:nGNX8FJmYl
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue